{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:30:34Z","timestamp":1781577034776,"version":"3.54.5"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1038\/s41575-021-00480-y","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T10:06:39Z","timestamp":1624961199000},"page":"705-715","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology"],"prefix":"10.1038","volume":"18","author":[{"given":"Markus F.","family":"Neurath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"key":"480_CR1","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1513\/AnnalsATS.202007-805OC","volume":"18","author":"NL Cobb","year":"2021","unstructured":"Cobb, N. L. et al. Comparison of clinical features and outcomes in critically ill patients hospitalized with COVID-19 versus influenza. Ann. Am. Thorac. Soc. 18, 632\u2013640 (2021).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"480_CR2","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1056\/NEJMoa2004500","volume":"382","author":"PK Bhatraju","year":"2020","unstructured":"Bhatraju, P. K. et al. Covid-19 in critically ill patients in the Seattle region \u2014 case series. N. Engl. J. Med. 382, 2012\u20132022 (2020).","journal-title":"N. Engl. J. Med."},{"key":"480_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579, 265\u2013269 (2020).","journal-title":"Nature"},{"key":"480_CR4","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan, W. J. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 382, 1708\u20131720 (2020).","journal-title":"N. Engl. J. Med."},{"key":"480_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","volume":"581","author":"R W\u00f6lfel","year":"2020","unstructured":"W\u00f6lfel, R. et al. Virological assessment of hospitalized patients with COVID-19. Nature 581, 465\u2013469 (2020).","journal-title":"Nature"},{"key":"480_CR6","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/s41591-020-0912-6","volume":"26","author":"J Zhou","year":"2020","unstructured":"Zhou, J. et al. Infection of bat and human intestinal organoids by SARS-CoV-2. Nat. Med. 26, 1077\u20131083 (2020).","journal-title":"Nat. Med."},{"key":"480_CR7","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","volume":"5","author":"Coronaviridae Study Group of the International Committee on Taxonomy of Viruses","year":"2020","unstructured":"Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536\u2013544 (2020).","journal-title":"Nat. Microbiol."},{"key":"480_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/pathogens9030240","volume":"9","author":"SU Rehman","year":"2020","unstructured":"Rehman, S. U., Shafique, L., Ihsan, A. & Liu, Q. Evolutionary Trajectory for the Emergence of Novel Coronavirus SARS-CoV-2. Pathogens 9, 240 (2020).","journal-title":"Pathogens"},{"key":"480_CR9","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1073\/pnas.2002589117","volume":"117","author":"S Matsuyama","year":"2020","unstructured":"Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl Acad. Sci. USA 117, 7001\u20137003 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"480_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17292-4","volume":"11","author":"S De Biasi","year":"2020","unstructured":"De Biasi, S. et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat. Commun. 11, 3434 (2020).","journal-title":"Nat. Commun."},{"key":"480_CR11","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 382, 1199\u20131207 (2020).","journal-title":"N. Engl. J. Med."},{"key":"480_CR12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00592-020-01636-z","volume":"58","author":"H Shah","year":"2021","unstructured":"Shah, H., Khan, M. S. H., Dhurandhar, N. V. & Hegde, V. The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19. Acta Diabetol. 58, 831\u2013843 (2021).","journal-title":"Acta Diabetol."},{"key":"480_CR13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565\u2013574 (2020).","journal-title":"Lancet"},{"key":"480_CR14","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","volume":"382","author":"HR Reynolds","year":"2020","unstructured":"Reynolds, H. R. et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N. Engl. J. Med. 382, 2441\u20132448 (2020).","journal-title":"N. Engl. J. Med."},{"key":"480_CR15","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444\u20131448 (2020).","journal-title":"Science"},{"key":"480_CR16","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"H Zhang","year":"2020","unstructured":"Zhang, H., Penninger, J. M., Li, Y., Zhong, N. & Slutsky, A. S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 46, 586\u2013590 (2020).","journal-title":"Intensive Care Med."},{"key":"480_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature11228","volume":"487","author":"T Hashimoto","year":"2012","unstructured":"Hashimoto, T. et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 487, 477\u2013481 (2012).","journal-title":"Nature"},{"key":"480_CR18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00011-009-0053-3","volume":"58","author":"JJ Byrnes","year":"2009","unstructured":"Byrnes, J. J. et al. Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice. Inflamm. Res. 58, 819\u2013827 (2009).","journal-title":"Inflamm. Res."},{"key":"480_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280 (2020).","journal-title":"Cell"},{"key":"480_CR20","first-page":"11","volume":"7","author":"YR Guo","year":"2020","unstructured":"Guo, Y. R. et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil. Med. Res. 7, 11 (2020).","journal-title":"Mil. Med. Res."},{"key":"480_CR21","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1053\/j.gastro.2020.04.045","volume":"159","author":"WD Redd","year":"2020","unstructured":"Redd, W. D. et al. Prevalence and characteristics of gastrointestinal symptoms in patients with severe acute respiratory syndrome coronavirus 2 infection in the United States: a multicenter cohort study. Gastroenterology 159, 765\u2013767 (2020).","journal-title":"Gastroenterology"},{"key":"480_CR22","doi-asserted-by":"publisher","first-page":"766","DOI":"10.14309\/ajg.0000000000000620","volume":"115","author":"L Pan","year":"2020","unstructured":"Pan, L. et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am. J. Gastroenterol. 115, 766\u2013773 (2020).","journal-title":"Am. J. Gastroenterol."},{"key":"480_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/MCG.0000000000001424","volume":"55","author":"ZY Dong","year":"2021","unstructured":"Dong, Z. Y., Xiang, B. J., Jiang, M., Sun, M. J. & Dai, C. The prevalence of gastrointestinal symptoms, abnormal liver function, digestive system disease and liver disease in COVID-19 infection: a systematic review and meta-analysis. J. Clin. Gastroenterol. 55, 67\u201376 (2021).","journal-title":"J. Clin. Gastroenterol."},{"key":"480_CR24","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1136\/gutjnl-2020-321269","volume":"69","author":"MF Neurath","year":"2020","unstructured":"Neurath, M. F. COVID-19 and immunomodulation in IBD. Gut 69, 1335\u20131342 (2020).","journal-title":"Gut"},{"key":"480_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/MCG.0000000000001462","volume":"55","author":"S Grover","year":"2021","unstructured":"Grover, S. et al. High prevalence of gastrointestinal manifestations of COVID-19 infection in hospitalized patients with cancer. J. Clin. Gastroenterol. 55, 84\u201387 (2021).","journal-title":"J. Clin. Gastroenterol."},{"key":"480_CR26","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1053\/j.gastro.2020.02.055","volume":"158","author":"F Xiao","year":"2020","unstructured":"Xiao, F. et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 158, 1831\u20131833 (2020).","journal-title":"Gastroenterology"},{"key":"480_CR27","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1053\/j.gastro.2020.10.021","volume":"160","author":"JV Patankar","year":"2021","unstructured":"Patankar, J. V. et al. The SARS-CoV-2 attachment receptor ACE2 is decreased in Crohn\u2019s disease and regulated by microbial and inflammatory signaling. Gastroenterology 160, 925\u2013928 (2021).","journal-title":"Gastroenterology"},{"key":"480_CR28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1126\/science.abc1669","volume":"369","author":"MM Lamers","year":"2020","unstructured":"Lamers, M. M. et al. SARS-CoV-2 productively infects human gut enterocytes. Science 369, 50\u201354 (2020).","journal-title":"Science"},{"key":"480_CR29","doi-asserted-by":"publisher","first-page":"104386","DOI":"10.1016\/j.jcv.2020.104386","volume":"128","author":"KP Patel","year":"2020","unstructured":"Patel, K. P. et al. Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19. J. Clin. Virol. 128, 104386 (2020).","journal-title":"J. Clin. Virol."},{"key":"480_CR30","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jhep.2020.04.006","volume":"73","author":"Q Cai","year":"2020","unstructured":"Cai, Q. et al. COVID-19: abnormal liver function tests. J. Hepatol 73, 566\u2013574 (2020).","journal-title":"J. Hepatol"},{"key":"480_CR31","first-page":"224","volume":"34","author":"S Yadlapati","year":"2021","unstructured":"Yadlapati, S. et al. Prevailing patterns of liver enzymes in patients with COVID-19 infection and association with clinical outcomes. Ann. Gastroenterol. 34, 224\u2013228 (2021).","journal-title":"Ann. Gastroenterol."},{"key":"480_CR32","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"480_CR33","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033\u20131034 (2020).","journal-title":"Lancet"},{"key":"480_CR34","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1002\/jcp.30047","volume":"236","author":"A Sadeghi","year":"2021","unstructured":"Sadeghi, A. et al. Th17 and Treg cells function in SARS-CoV2 patients compared with healthy controls. J. Cell. Physiol. 236, 2829\u20132839 (2021).","journal-title":"J. Cell. Physiol."},{"key":"480_CR35","doi-asserted-by":"publisher","first-page":"eabe1670","DOI":"10.1126\/sciimmunol.abe1670","volume":"5","author":"T Parrot","year":"2020","unstructured":"Parrot, T. et al. MAIT cell activation and dynamics associated with COVID-19 disease severity. Sci. Immunol. 5, eabe1670 (2020).","journal-title":"Sci. Immunol."},{"key":"480_CR36","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140329","volume":"5","author":"KE Remy","year":"2020","unstructured":"Remy, K. E. et al. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCI Insight 5, e140329 (2020).","journal-title":"JCI Insight"},{"key":"480_CR37","doi-asserted-by":"publisher","first-page":"102925","DOI":"10.1016\/j.ebiom.2020.102925","volume":"58","author":"M Leppkes","year":"2020","unstructured":"Leppkes, M. et al. Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine 58, 102925 (2020).","journal-title":"EBioMedicine"},{"key":"480_CR38","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1016\/S2666-5247(20)30144-0","volume":"1","author":"B Schurink","year":"2020","unstructured":"Schurink, B. et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe 1, e290\u2013e299 (2020).","journal-title":"Lancet Microbe"},{"key":"480_CR39","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41577-020-00460-4","volume":"20","author":"M Lipsitch","year":"2020","unstructured":"Lipsitch, M., Grad, Y. H., Sette, A. & Crotty, S. Cross-reactive memory T cells and herd immunity to SARS-CoV-2. Nat. Rev. Immunol. 20, 709\u2013713 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"480_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/jpids\/piaa115","volume":"10","author":"K Chiotos","year":"2021","unstructured":"Chiotos, K. et al. Multicenter interim guidance on use of antivirals for children with coronavirus disease 2019\/severe acute respiratory syndrome coronavirus 2. J. Pediatric Infect. Dis. Soc. 10, 34\u201348 (2021).","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"480_CR41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S2352-4642(20)30304-7","volume":"5","author":"R Harwood","year":"2021","unstructured":"Harwood, R. et al. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc. Health 5, 133\u2013141 (2021).","journal-title":"Lancet Child Adolesc. Health"},{"key":"480_CR42","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183, 158\u201368 (2020).","journal-title":"Cell"},{"key":"480_CR43","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/s41590-020-0798-y","volume":"21","author":"L Swadling","year":"2020","unstructured":"Swadling, L. & Maini, M. K. T cells in COVID-19 - united in diversity. Nat. Immunol. 21, 1307\u20131308 (2020).","journal-title":"Nat. Immunol."},{"key":"480_CR44","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501 (2020).","journal-title":"Cell"},{"key":"480_CR45","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/s41590-020-0762-x","volume":"21","author":"JY Zhang","year":"2020","unstructured":"Zhang, J. Y. et al. Single-cell landscape of immunological responses in patients with COVID-19. Nat. Immunol. 21, 1107\u20131118 (2020).","journal-title":"Nat. Immunol."},{"key":"480_CR46","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","volume":"21","author":"Y Peng","year":"2020","unstructured":"Peng, Y. et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336\u20131345 (2020).","journal-title":"Nat. Immunol."},{"key":"480_CR47","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41591-020-01143-2","volume":"27","author":"I Schulien","year":"2020","unstructured":"Schulien, I. et al. Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells. Nat. Med. 27, 78\u201385 (2020).","journal-title":"Nat. Med."},{"key":"480_CR48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/JLB.4COVCRA0820-481RRR","volume":"109","author":"Z Parackova","year":"2021","unstructured":"Parackova, Z., Bloomfield, M., Klocperk, A. & Sediva, A. Neutrophils mediate Th17 promotion in COVID-19 patients. J. Leukoc. Biol. 109, 73\u201376 (2021).","journal-title":"J. Leukoc. Biol."},{"key":"480_CR49","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-020-03065-y","volume":"591","author":"E Pairo-Castineira","year":"2021","unstructured":"Pairo-Castineira, E. et al. Genetic mechanisms of critical illness in Covid-19. Nature 591, 92\u201398 (2021).","journal-title":"Nature"},{"key":"480_CR50","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586, 594\u2013599 (2020).","journal-title":"Nature"},{"key":"480_CR51","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.cell.2020.10.001","volume":"183","author":"BJ Meckiff","year":"2020","unstructured":"Meckiff, B. J. et al. Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19. Cell 183, 1340\u201313536 (2020).","journal-title":"Cell"},{"key":"480_CR52","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1172\/JCI137647","volume":"130","author":"SF Pedersen","year":"2020","unstructured":"Pedersen, S. F. & Ho, Y. C. SARS-CoV-2: a storm is raging. J. Clin. Invest. 130, 2202\u20132205 (2020).","journal-title":"J. Clin. Invest."},{"key":"480_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17703-6","volume":"11","author":"D Simon","year":"2020","unstructured":"Simon, D. et al. Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat. Commun. 11, 3774 (2020).","journal-title":"Nat. Commun."},{"key":"480_CR54","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1053\/j.gastro.2020.10.041","volume":"160","author":"AA Potdar","year":"2021","unstructured":"Potdar, A. A. et al. Altered intestinal ACE2 levels are associated with inflammation, severe disease, and response to anti-cytokine therapy in inflammatory bowel disease. Gastroenterology 160, 809\u2013822 (2021).","journal-title":"Gastroenterology"},{"key":"480_CR55","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/ibd\/izaa085","volume":"26","author":"JF Burgueno","year":"2020","unstructured":"Burgueno, J. F. et al. Expression of SARS-CoV-2 entry molecules ACE2 and TMPRSS2 in the gut of patients with IBD. Inflamm. Bowel Dis. 26, 797\u2013808 (2020).","journal-title":"Inflamm. Bowel Dis."},{"key":"480_CR56","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1053\/j.gastro.2020.05.030","volume":"159","author":"JK Nowak","year":"2020","unstructured":"Nowak, J. K. et al. Age, inflammation, and disease location are critical determinants of intestinal expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in inflammatory bowel disease. Gastroenterology 159, 1151\u20131154 (2020).","journal-title":"Gastroenterology"},{"key":"480_CR57","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/ecco-jcc\/jjaa185","volume":"15","author":"B Verstockt","year":"2021","unstructured":"Verstockt, B. et al. Intestinal receptor of SARS-CoV-2 in inflamed IBD tissue seems downregulated by HNF4A in ileum and upregulated by interferon regulating factors in colon. J. Crohns Colitis 15, 485\u2013498 (2021).","journal-title":"J. Crohns Colitis"},{"key":"480_CR58","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.gastro.2020.09.029","volume":"160","author":"M Suarez-Farinas","year":"2021","unstructured":"Suarez-Farinas, M. et al. Intestinal inflammation modulates the expression of ACE2 and TMPRSS2 and potentially overlaps with the pathogenesis of SARS-CoV-2-related disease. Gastroenterology 160, 287\u2013301 (2021).","journal-title":"Gastroenterology"},{"key":"480_CR59","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1042\/CS20200163","volume":"134","author":"D Batlle","year":"2020","unstructured":"Batlle, D., Wysocki, J. & Satchell, K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin. Sci. 134, 543\u2013545 (2020).","journal-title":"Clin. Sci."},{"key":"480_CR60","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/gutjnl-2019-318512","volume":"69","author":"M Garg","year":"2019","unstructured":"Garg, M. et al. Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target? Gut 69, 841\u2013851 (2019).","journal-title":"Gut"},{"key":"480_CR61","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2468-1253(20)30121-7","volume":"5","author":"P An","year":"2020","unstructured":"An, P. et al. Protection of 318 inflammatory bowel disease patients from the outbreak and rapid spread of COVID-19 infection in Wuhan, China. Lancet Gastroenterol. Hepatol. 5, 525\u2013527 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"480_CR62","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/ecco-jcc\/jjaa237","volume":"15","author":"R Berte","year":"2021","unstructured":"Berte, R. et al. Seroprevalence of SARS-CoV2 in IBD patients treated with biological therapy. J. Crohns Colitis 15, 864\u2013868 (2021).","journal-title":"J. Crohns Colitis"},{"key":"480_CR63","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/ibd\/izaa221","volume":"27","author":"I Guerra","year":"2021","unstructured":"Guerra, I. et al. Incidence, clinical characteristics, and evolution of SARS-CoV-2 infection in patients with inflammatory bowel disease: a single-center study in Madrid, Spain. Inflamm. Bowel Dis. 27, 25\u201333 (2021).","journal-title":"Inflamm. Bowel Dis."},{"key":"480_CR64","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.3390\/jcm9113533","volume":"9","author":"M Allocca","year":"2020","unstructured":"Allocca, M. et al. Patients with inflammatory bowel disease are not at increased risk of COVID-19: a large multinational cohort study. J. Clin. Med. 9, 3533 (2020).","journal-title":"J. Clin. Med."},{"key":"480_CR65","doi-asserted-by":"publisher","first-page":"808","DOI":"10.14309\/ajg.0000000000001012","volume":"116","author":"N Khan","year":"2021","unstructured":"Khan, N. et al. Are patients with inflammatory bowel disease at an increased risk of developing SARS-CoV-2 than patients without inflammatory bowel disease? Results from a nationwide Veterans\u2019 Affairs Cohort Study. Am. J. Gastroenterol. 116, 808\u2013810 (2021).","journal-title":"Am. J. Gastroenterol."},{"key":"480_CR66","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.cgh.2020.10.010","volume":"19","author":"EJ Brenner","year":"2020","unstructured":"Brenner, E. J. et al. Benign evolution of SARS-Cov2 infections in children with inflammatory bowel disease: results from two international databases. Clin. Gastroenterol. Hepatol. 19, 394\u2013396 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"480_CR67","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/ibd\/izaa278","volume":"27","author":"KE Burke","year":"2020","unstructured":"Burke, K. E. et al. Immunosuppressive therapy and risk of COVID-19 infection in patients with inflammatory bowel diseases. Inflamm. Bowel Dis. 27, 155\u2013161 (2020).","journal-title":"Inflamm. Bowel Dis."},{"key":"480_CR68","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/ecco-jcc\/jjaa215","volume":"15","author":"L Derikx","year":"2021","unstructured":"Derikx, L. et al. Clinical outcomes of Covid-19 in patients with inflammatory bowel disease: a nationwide cohort study. J. Crohns Colitis 15, 529\u2013539 (2021).","journal-title":"J. Crohns Colitis"},{"key":"480_CR69","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1136\/gutjnl-2020-321411","volume":"69","author":"C Bezzio","year":"2020","unstructured":"Bezzio, C. et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut 69, 1213\u20131217 (2020).","journal-title":"Gut"},{"key":"480_CR70","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.dld.2020.12.120","volume":"53","author":"F Bossa","year":"2021","unstructured":"Bossa, F. et al. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. Dig. Liver Dis. 53, 277\u2013282 (2021).","journal-title":"Dig. Liver Dis."},{"key":"480_CR71","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/gutjnl-2020-322539","volume":"70","author":"RC Ungaro","year":"2021","unstructured":"Ungaro, R. C. et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 70, 725\u2013732 (2021).","journal-title":"Gut"},{"key":"480_CR72","unstructured":"Brenner, E. J., Ungaro, R. C., Colombel, J. F. & Kappelman, M. D. SECURE-IBD Database Public Data Update. covidibd.org (2 May 2021)."},{"key":"480_CR73","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan, B. G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369, 699\u2013710 (2013).","journal-title":"N. Engl. J. Med."},{"key":"480_CR74","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn, W. J. et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N. Engl. J. Med. 369, 711\u2013721 (2013).","journal-title":"N. Engl. J. Med."},{"key":"480_CR75","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1136\/gutjnl-2018-317977","volume":"68","author":"S Zundler","year":"2019","unstructured":"Zundler, S., Becker, E., Schulze, L. L. & Neurath, M. F. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut 68, 1688\u20131700 (2019).","journal-title":"Gut"},{"key":"480_CR76","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1136\/gutjnl-2015-310022","volume":"65","author":"A Fischer","year":"2016","unstructured":"Fischer, A. et al. Differential effects of \u03b14\u03b27 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut 65, 1642\u20131664 (2016).","journal-title":"Gut"},{"key":"480_CR77","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn, W. J. et al. Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease. N. Engl. J. Med. 367, 1519\u20131528 (2012).","journal-title":"N. Engl. J. Med."},{"key":"480_CR78","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands, B. E. et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 381, 1201\u20131214 (2019).","journal-title":"N. Engl. J. Med."},{"key":"480_CR79","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/s41590-019-0415-0","volume":"20","author":"MF Neurath","year":"2019","unstructured":"Neurath, M. F. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat. Immunol. 20, 970\u2013979 (2019).","journal-title":"Nat. Immunol."},{"key":"480_CR80","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/ibd\/izaa303","volume":"27","author":"M Agrawal","year":"2021","unstructured":"Agrawal, M. et al. Characteristics and outcomes of IBD patients with COVID-19 on tofacitinib therapy in the SECURE-IBD Registry. Inflamm. Bowel Dis. 27, 585\u2013589 (2021).","journal-title":"Inflamm. Bowel Dis."},{"key":"480_CR81","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.antiviral.2014.12.011","volume":"115","author":"KW Cheng","year":"2015","unstructured":"Cheng, K. W. et al. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antivir. Res. 115, 9\u201316 (2015).","journal-title":"Antivir. Res."},{"key":"480_CR82","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.virusres.2014.02.010","volume":"184","author":"J Carbajo-Lozoya","year":"2014","unstructured":"Carbajo-Lozoya, J. et al. Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. Virus Res. 184, 44\u201353 (2014).","journal-title":"Virus Res."},{"key":"480_CR83","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(20)30858-8","volume":"395","author":"M Feldmann","year":"2020","unstructured":"Feldmann, M. et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet 395, 1407\u20131409 (2020).","journal-title":"Lancet"},{"key":"480_CR84","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","volume":"181","author":"C Salvarani","year":"2021","unstructured":"Salvarani, C. et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern. Med. 181, 24\u201331 (2021).","journal-title":"JAMA Intern. Med."},{"key":"480_CR85","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","volume":"383","author":"JH Stone","year":"2020","unstructured":"Stone, J. H. et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N. Engl. J. Med. 383, 2333\u20132344 (2020).","journal-title":"N. Engl. J. Med."},{"key":"480_CR86","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","volume":"384","author":"C Salama","year":"2021","unstructured":"Salama, C. et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N. Engl. J. Med. 384, 20\u201330 (2021).","journal-title":"N. Engl. J. Med."},{"key":"480_CR87","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N. Engl. J. Med. 384, 795\u2013807 (2021).","journal-title":"N. Engl. J. Med."},{"key":"480_CR88","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/MPG.0000000000002809","volume":"71","author":"MT Dolinger","year":"2020","unstructured":"Dolinger, M. T. et al. Pediatric Crohn disease and multisystem inflammatory syndrome in children (MIS-C) and COVID-19 treated with infliximab. J. Ped. Gastroenterol. Nutr. 71, 153\u2013155 (2020).","journal-title":"J. Ped. Gastroenterol. Nutr."},{"key":"480_CR89","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000508740","volume":"36","author":"A Abdullah","year":"2020","unstructured":"Abdullah, A., Neurath, M. F. & Atreya, R. Mild COVID-19 symptoms in an infliximab-treated ulcerative colitis patient: can ongoing anti-TNF therapy protect against the viral hyperinflammatory response and avoid aggravated outcomes? Visc. Med. 36, 338\u2013342 (2020).","journal-title":"Visc. Med."},{"key":"480_CR90","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10875-020-00927-y","volume":"41","author":"E Monreal","year":"2020","unstructured":"Monreal, E. et al. The impact of immunosuppression and autoimmune disease on severe outcomes in patients hospitalized with COVID-19. J. Clin. Immunol. 41, 315\u2013323 (2020).","journal-title":"J. Clin. Immunol."},{"key":"480_CR91","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jdcr.2020.10.032","volume":"7","author":"M Ward","year":"2021","unstructured":"Ward, M. & Gooderham, M. Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of interleukin 23. JAAD Case Rep. 7, 60\u201361 (2021).","journal-title":"JAAD Case Rep."},{"key":"480_CR92","volume":"33","author":"CJ Wang","year":"2020","unstructured":"Wang, C. J. & Truong, A. K. COVID-19 infection on IL-23 inhibition. Dermatol Ther. 33, e13893 (2020).","journal-title":"Dermatol Ther."},{"key":"480_CR93","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1111\/jdv.16468","volume":"34","author":"F Messina","year":"2020","unstructured":"Messina, F. & Piaserico, S. SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor. J. Eur. Acad. Dermatol. Venereol. 34, e254\u2013e255 (2020).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"480_CR94","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.gastro.2020.04.012","volume":"159","author":"DT Rubin","year":"2020","unstructured":"Rubin, D. T., Feuerstein, J. D., Wang, A. Y. & Cohen, R. D. AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary. Gastroenterology 159, 350\u2013357 (2020).","journal-title":"Gastroenterology"},{"key":"480_CR95","doi-asserted-by":"publisher","first-page":"S798","DOI":"10.1093\/ecco-jcc\/jjaa160","volume":"14","author":"F Magro","year":"2020","unstructured":"Magro, F. et al. Inflammatory bowel disease management during the COVID-19 outbreak: the ten do\u2019s and don\u2019ts from the ECCO-COVID Taskforce. J. Crohns Colitis 14, S798\u2013S806 (2020).","journal-title":"J. Crohns Colitis"},{"key":"480_CR96","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/hep4.1557","volume":"4","author":"A Gerussi","year":"2020","unstructured":"Gerussi, A. et al. Coronavirus disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients. Hepatol. Commun. 4, 1257\u20131262 (2020).","journal-title":"Hepatol. Commun."},{"key":"480_CR97","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jhep.2020.08.035","volume":"74","author":"X Verhelst","year":"2021","unstructured":"Verhelst, X., Somers, N., Geerts, A., Degroote, H. & Van Vlierberghe, H. Health status of patients with autoimmune hepatitis is not affected by the SARS-CoV-2 outbreak in Flanders, Belgium. J. Hepatol. 74, 240\u2013241 (2021).","journal-title":"J. Hepatol."},{"key":"480_CR98","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jhep.2021.01.021","volume":"74","author":"T Marjot","year":"2021","unstructured":"Marjot, T. et al. SARS-CoV-2 infection in patients with autoimmune hepatitis. J. Hepatol. 74, 1335\u20131343 (2021).","journal-title":"J. Hepatol."},{"key":"480_CR99","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jhep.2020.04.002","volume":"73","author":"A Lleo","year":"2020","unstructured":"Lleo, A., Invernizzi, P., Lohse, A. W., Aghemo, A. & Carbone, M. Management of patients with autoimmune liver disease during COVID-19 pandemic. J. Hepatol. 73, 453\u2013455 (2020).","journal-title":"J. Hepatol."},{"key":"480_CR100","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/MCG.0000000000001481","volume":"55","author":"A Mohammed","year":"2021","unstructured":"Mohammed, A., Paranji, N., Chen, P. H. & Niu, B. COVID-19 in chronic liver disease and liver transplantation: a clinical review. J. Clin. Gastroenterol. 55, 187\u2013194 (2021).","journal-title":"J. Clin. Gastroenterol."},{"key":"480_CR101","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s12072-020-10054-w","volume":"14","author":"AC-T Force","year":"2020","unstructured":"Force, A. C.-T., Lau, G. & Sharma, M. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hepatol. Int. 14, 415\u2013428 (2020).","journal-title":"Hepatol. Int."},{"key":"480_CR102","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMc2011117","volume":"382","author":"E Akalin","year":"2020","unstructured":"Akalin, E. et al. Covid-19 and kidney transplantation. N. Engl. J. Med. 382, 2475\u20132477 (2020).","journal-title":"N. Engl. J. Med."},{"key":"480_CR103","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1111\/ajt.15929","volume":"20","author":"M Fernandez-Ruiz","year":"2020","unstructured":"Fernandez-Ruiz, M. et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. Am. J. Transplant. 20, 1849\u20131858 (2020).","journal-title":"Am. J. Transplant."},{"key":"480_CR104","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1111\/ajt.16369","volume":"21","author":"E Coll","year":"2021","unstructured":"Coll, E. et al. COVID-19 in transplant recipients: the Spanish experience. Am. J. Transplant. 21, 1825\u20131837 (2021).","journal-title":"Am. J. Transplant."},{"key":"480_CR105","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/TP.0000000000003527","volume":"105","author":"SA Mehta","year":"2021","unstructured":"Mehta, S. A. et al. Incidence and outcomes of COVID-19 in kidney and liver transplant recipients with HIV: report from the National HOPE in Action Consortium. Transplantation 105, 216\u2013224 (2021).","journal-title":"Transplantation"},{"key":"480_CR106","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/TP.0000000000003339","volume":"104","author":"SG Yi","year":"2020","unstructured":"Yi, S. G. et al. Early experience with COVID-19 and solid organ transplantation at a US high-volume transplant center. Transplantation 104, 2208\u20132214 (2020).","journal-title":"Transplantation"},{"key":"480_CR107","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/TP.0000000000003460","volume":"105","author":"M Miarons","year":"2020","unstructured":"Miarons, M. et al. COVID-19 in solid organ transplantation: a matched retrospective cohort study and evaluation of immunosuppression management. Transplantation 105, 138\u2013150 (2020).","journal-title":"Transplantation"},{"key":"480_CR108","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.gastrohep.2020.06.003","volume":"43","author":"X Forns","year":"2020","unstructured":"Forns, X. & Navasa, M. Liver transplant immunosuppression during the covid-19 pandemic. Gastroenterol. Hepatol. 43, 457\u2013463 (2020).","journal-title":"Gastroenterol. Hepatol."},{"key":"480_CR109","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41575-020-0347-z","volume":"17","author":"T Di Maira","year":"2020","unstructured":"Di Maira, T. & Berenguer, M. COVID-19 and liver transplantation. Nat. Rev. Gastroenterol. Hepatol. 17, 526\u2013528 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"480_CR110","doi-asserted-by":"publisher","first-page":"870","DOI":"10.4254\/wjh.v12.i10.870","volume":"12","author":"F Alconchel","year":"2020","unstructured":"Alconchel, F. et al. Severe COVID-19 after liver transplantation, surviving the pitfalls of learning on-the-go: three case reports. World J. Hepatol. 12, 870\u2013879 (2020).","journal-title":"World J. Hepatol."},{"key":"480_CR111","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13492","volume":"23","author":"A Dhand","year":"2021","unstructured":"Dhand, A. et al. Successful liver transplantation in a patient recovered from COVID-19. Transpl. Infect. Dis. 23, e13492 (2021).","journal-title":"Transpl. Infect. Dis."},{"key":"480_CR112","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1111\/ajt.16349","volume":"21","author":"H Niess","year":"2020","unstructured":"Niess, H. et al. Liver transplantation in a patient after COVID-19 \u2014 rapid loss of antibodies and prolonged viral RNA shedding. Am. J. Transplant. 21, 1629\u20131632 (2020).","journal-title":"Am. J. Transplant."},{"key":"480_CR113","doi-asserted-by":"publisher","DOI":"10.21037\/apm-20-996","author":"L Wei","year":"2020","unstructured":"Wei, L., Liu, B., Zhao, Y. & Chen, Z. Prolonged shedding of SARS-CoV-2 in an elderly liver transplant patient infected by COVID-19: a case report. Ann. Palliat. Med. https:\/\/doi.org\/10.21037\/apm-20-996 (2020).","journal-title":"Ann. Palliat. Med."},{"key":"480_CR114","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1136\/gutjnl-2020-321923","volume":"69","author":"C Becchetti","year":"2020","unstructured":"Becchetti, C. et al. COVID-19 in an international European liver transplant recipient cohort. Gut 69, 1832\u20131840 (2020).","journal-title":"Gut"},{"key":"480_CR115","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","volume":"31","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann. Oncol. 31, 894\u2013901 (2020).","journal-title":"Ann. Oncol."},{"key":"480_CR116","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2021.1899442","author":"C Nahshon","year":"2021","unstructured":"Nahshon, C. et al. Outcomes of diagnosed COVID-19 cancer patients: concerning results of a systematic review. J. Chemother. https:\/\/doi.org\/10.1080\/1120009X.2021.1899442 (2021).","journal-title":"J. Chemother."},{"key":"480_CR117","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jhep.2020.07.040","volume":"74","author":"J Colmenero","year":"2020","unstructured":"Colmenero, J. et al. Epidemiological pattern, incidence and outcomes of COVID-19 in liver transplant patients. J. Hepatol. 74, 148\u2013155 (2020).","journal-title":"J. Hepatol."},{"issue":"Suppl. 2","key":"480_CR118","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/01.tp.0000186390.10150.66","volume":"80","author":"AC Allison","year":"2005","unstructured":"Allison, A. C. & Eugui, E. M. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 80 (Suppl. 2), 181\u2013190 (2005).","journal-title":"Transplantation"},{"key":"480_CR119","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S2468-1253(20)30271-5","volume":"5","author":"GJ Webb","year":"2020","unstructured":"Webb, G. J. et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol. Hepatol. 5, 1008\u20131016 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"480_CR120","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1053\/j.gastro.2020.11.045","volume":"160","author":"LS Belli","year":"2021","unstructured":"Belli, L. S. et al. Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA\/ELTR multi-center European study. Gastroenterology 160, 1151\u20131163 (2021).","journal-title":"Gastroenterology"},{"key":"480_CR121","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1136\/gutjnl-2020-322620","volume":"70","author":"M Rodriguez-Peralvarez","year":"2021","unstructured":"Rodriguez-Peralvarez, M., Salcedo, M., Colmenero, J. & Pons, J. A. Modulating immunosuppression in liver transplant patients with COVID-19. Gut 70, 1412\u20131414 (2021).","journal-title":"Gut"},{"key":"480_CR122","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/TP.0000000000003523","volume":"105","author":"Y Azzi","year":"2021","unstructured":"Azzi, Y., Bartash, R., Scalea, J., Loarte-Campos, P. & Akalin, E. COVID-19 and solid organ transplantation: a review article. Transplantation 105, 37\u201355 (2021).","journal-title":"Transplantation"},{"key":"480_CR123","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1053\/j.gastro.2020.05.066","volume":"159","author":"DJ Lukin","year":"2020","unstructured":"Lukin, D. J. et al. Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease. Gastroenterology 159, 1541\u20131544 (2020).","journal-title":"Gastroenterology"},{"key":"480_CR124","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2020.05.032","volume":"159","author":"EJ Brenner","year":"2020","unstructured":"Brenner, E. J. et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 159, 481\u2013491 (2020).","journal-title":"Gastroenterology"},{"key":"480_CR125","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41577-020-0312-7","volume":"20","author":"G Schett","year":"2020","unstructured":"Schett, G., Sticherling, M. & Neurath, M. F. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat. Rev. Immunol. 20, 271\u2013272 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"480_CR126","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Horby, P. et al. Dexamethasone in hospitalized patients with Covid-19 \u2014 preliminary report. N. Engl. J. Med. 384, 693\u2013704 (2021).","journal-title":"N. Engl. J. Med."},{"key":"480_CR127","doi-asserted-by":"publisher","first-page":"571156","DOI":"10.3389\/fphar.2020.571156","volume":"11","author":"W Cheng","year":"2020","unstructured":"Cheng, W. et al. Efficacy and safety of corticosteroid treatment in patients with COVID-19: a systematic review and meta-analysis. Front. Pharmacol. 11, 571156 (2020).","journal-title":"Front. Pharmacol."},{"key":"480_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78054-2","volume":"10","author":"H Shuto","year":"2020","unstructured":"Shuto, H. et al. A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19. Sci. Rep. 10, 20935 (2020).","journal-title":"Sci. Rep."},{"key":"480_CR129","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41577-020-00455-1","volume":"20","author":"EPK Parker","year":"2020","unstructured":"Parker, E. P. K., Shrotri, M. & Kampmann, B. Keeping track of the SARS-CoV-2 vaccine pipeline. Nat. Rev. Immunol. 20, 650 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"480_CR130","doi-asserted-by":"publisher","first-page":"n296","DOI":"10.1136\/bmj.n296","volume":"372","author":"E Mahase","year":"2021","unstructured":"Mahase, E. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ 372, n296 (2021).","journal-title":"BMJ"},{"key":"480_CR131","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397, 671\u2013681 (2021).","journal-title":"Lancet"},{"key":"480_CR132","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S2468-1253(21)00024-8","volume":"6","author":"JL Alexander","year":"2021","unstructured":"Alexander, J. L. et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol. Hepatol. 6, 218\u2013224 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"480_CR133","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/ibd.21800","volume":"18","author":"G Fiorino","year":"2012","unstructured":"Fiorino, G. et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm. Bowel Dis. 18, 1042\u20131047 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"480_CR134","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1136\/gutjnl-2011-300256","volume":"61","author":"G Cullen","year":"2012","unstructured":"Cullen, G., Bader, C., Korzenik, J. R. & Sands, B. E. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut 61, 385\u2013391 (2012).","journal-title":"Gut"},{"key":"480_CR135","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/gutjnl-2021-324388","volume":"70","author":"NA Kennedy","year":"2021","unstructured":"Kennedy, N. A. et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut 70, 865\u2013875 (2021).","journal-title":"Gut"},{"key":"480_CR136","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31751","author":"OK Fix","year":"2021","unstructured":"Fix, O. K. et al. AASLD Expert Panel consensus statement: vaccines to prevent COVID-19 infection in patients with liver disease. Hepatology https:\/\/doi.org\/10.1002\/hep.31751 (2021).","journal-title":"Hepatology"},{"key":"480_CR137","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/gutjnl-2020-324000","volume":"70","author":"CA Siegel","year":"2021","unstructured":"Siegel, C. A. et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut 70, 635\u2013640 (2021).","journal-title":"Gut"},{"key":"480_CR138","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","volume":"135","author":"WJ Sandborn","year":"2008","unstructured":"Sandborn, W. J. et al. A randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease. Gastroenterology 135, 1130\u20131141 (2008).","journal-title":"Gastroenterology"},{"key":"480_CR139","doi-asserted-by":"publisher","first-page":"m3379","DOI":"10.1136\/bmj.m3379","volume":"370","author":"B Rochwerg","year":"2020","unstructured":"Rochwerg, B. et al. A living WHO guideline on drugs for covid-19. BMJ 370, m3379 (2020).","journal-title":"BMJ"}],"container-title":["Nature Reviews Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-021-00480-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-021-00480-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-021-00480-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T13:02:35Z","timestamp":1634043755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-021-00480-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":139,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["480"],"URL":"https:\/\/doi.org\/10.1038\/s41575-021-00480-y","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]},"assertion":[{"value":"7 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.F.N. has served as an advisor for Abbvie, Pentax, Giuliani, MSD, Takeda, Roche and Boehringer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}